Inarigivir ammonium 是一种二核苷酸抗病毒化合物，可显着降低表达乙型肝炎病毒的转基因小鼠的 HBV DNA。它是一种激活细胞内先天免疫的视黄酸诱导基因-I 激动剂。

Inarigivir ammonium is a dinucleotide antiviral compound that significantly reduces HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir is an agonist of retinoic acid-inducible gene-I (RIG-I) that activates intracellular innate immunity.

Inarigivir is active against HBV variants carrying resistance markers against all the nucleos(t)ide analogues approved for treating chronic hepatitis B[1].

Administration of 100 mg/kg/day Inarigivir (ip) significantly reduces viral DNA in the liver and shows anti-HBV activity while serum HBV DNA is not reduced. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values[2].

2172788-92-8

Inarigivir铵;SB-9200 ammonium;ORI-9020 ammonium

DMSO:98 mg/mL (162.11 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years